Charles Schwab Investment Management Inc. Has $444,000 Stake in 908 Devices Inc. (NASDAQ:MASS)

Charles Schwab Investment Management Inc. lowered its position in 908 Devices Inc. (NASDAQ:MASS) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 201,768 shares of the company’s stock after selling 18,709 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.58% of 908 Devices worth $444,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. acquired a new stake in 908 Devices in the 3rd quarter valued at about $45,000. Townsquare Capital LLC bought a new stake in 908 Devices in the third quarter valued at approximately $50,000. Concurrent Investment Advisors LLC acquired a new stake in shares of 908 Devices in the fourth quarter valued at approximately $52,000. Barclays PLC increased its holdings in shares of 908 Devices by 452.7% during the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after acquiring an additional 37,853 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in 908 Devices during the 3rd quarter valued at $190,000. Institutional investors own 88.06% of the company’s stock.

908 Devices Price Performance

MASS stock opened at $4.48 on Tuesday. The business’s fifty day moving average price is $3.09 and its two-hundred day moving average price is $2.95. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.56. The stock has a market capitalization of $158.28 million, a price-to-earnings ratio of -2.53 and a beta of 0.99.

Analysts Set New Price Targets

MASS has been the subject of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of 908 Devices in a research note on Saturday, March 22nd. Stephens reissued an “overweight” rating and issued a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $5.33.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.